Upper gastrointestinal cancer predisposition syndromes

Hematology/Oncology Clinics of North America

Volumn 24, Issue 5, 2010, Pages 815-835

  Shah, Manish A ^a,b   Kurtz, Robert C ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cancer; Gastrointestinal; Genetic predisposition; Hereditary; Malignancy

Indexed keywords

ARGININE; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOGLOBIN; HISTIDINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN MLH1; PROTEIN MSH2; UVOMORULIN;

AMINO ACID SUBSTITUTION; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMOSOME 16Q; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA SYNDROME; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; FAMILY HISTORY; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC TRANSCRIPTION; HELICOBACTER INFECTION; HEREDITARY DIFFUSE GASTRIC CANCER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; LINKAGE ANALYSIS; MICROSATELLITE INSTABILITY; MISSENSE MUTATION; OBESITY; ONCOGENE C KIT; PANCREAS CANCER; PANCREATITIS; PATHOGENESIS; PENETRANCE; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; TYLOSIS; UPPER GASTROINTESTINAL TRACT;

GASTROINTESTINAL NEOPLASMS; GENETIC LINKAGE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; NEOPLASTIC SYNDROMES, HEREDITARY; PENETRANCE;

EID: 77956301557     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.06.007     Document Type: Review

References (142)

1. Blot W.J., DeVesa S.S., Kneller R.W., et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991, 265:1287-1289.
2. Blot W.J., McLaughlin J.K. The changing epidemiology of esophageal cancer. Semin Oncol 1999, 26:2-13.
3. Brown L.M., Devesa S.S., Chow W.H. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008, 100:1184-1187.
4. Crew K.D., Neugut A.I. Epidemiology of gastric cancer. World J Gastroenterol 2006, 12(3):354-362.
5. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249.
6. Clarke C.A., McConnell R.B. Six cases of carcinoma of the oesophagus occurring in one family. Br Med J 1954, 2:1137-1138.
7. Stevens H.P., Kelsell D.P., Bryant S.P., et al. Linkage of an American pedigree with palmo-plantar keratoderma and malignancy (palmoplantar ectodermal dysplasia type III) to 17q24. Literature survey and proposed updated classification of the keratodermas. Arch Dermatol 1996, 132:640-651.
8. Hennies H.C., Hagedorn M., Reis A. Palmoplantar keratoderma in association with carcinoma of the oesophagus maps to chromosome 17q distal to the keratin gene cluster. Genomics 1995, 29:537-540.
9. Ellis A., Field J.K., Field A.E., et al. Tylosis associated with carcinoma of the oesophagus and oral leukoplakia in a large Liverpool family - a review of six generations. Eur J Cancer B Oral Oncol 1994, 30:102-111.
10. Robertson E.V., Jankowski J.A. Genetics of gastroesophageal cancer: paradigms, paradoxes, and prognostic utility. Am J Gastroenterol 2008, 103:443-449.
11. Risk J.M., Evans K.E., Jones J., et al. Characterization of a 500kb region on 17q25 and the exclusion of candidate genes as the familial tylosis oesophageal cancer (TOC) locus. Oncogene 2002, 21:6395-6402.
12. Langan J.E., Cole C.G., Huckle E.J., et al. Novel microsatellite markers and single nucleotide polymorphisms refine the tylosis with oesophageal cancer (TOC) minimal region on 17q25 to 42.5kb: sequencing does not identify causative gene. Hum Genet 2004, 114:534-540.
13. McRonald F.E., Liloglou T., Xinarianos G., et al. Down-regulation of the cytoglobin gene, located on 17q25, in tylosis with oesophageal cancer (TOC): evidence for transallele repression. Hum Mol Genet 2006, 15:1271-1277.
14. Stratton M.R., Ford D., Neuhasen S., et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet 1994, 7(1):103-107.
15. Chen P.L., Chen C.F., Chen Y., et al. The BRC repeats in BRCA2 are critical for Rad51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A 1998, 95(9):5287-5292.
16. Boulton S.J. Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans 2006, 34(5):633-645.
17. Nan H., Wang C., Han X-Y., et al. Evaluation of BRCA2 in the genetic susceptibility of familial esophageal cancer. Oncogene 2004, 23:852-858.
18. Akbari M.R., Malekzadeh R., Nasrollahzadeh D., et al. Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma. Oncogene 2008, 27(9):1290-1296.
19. Cameron A.J., Romero Y. Symptomatic gastro-oesophageal reflux as a risk factor for oesophageal adenocarcinoma. Gut 2000, 46(6):754-755.
20. Chak A., Faulx A., Kinnard M., et al. Identification of Barrett's esophagus in relatives by endoscopic screening. Am J Gastroenterol 2004, 99:2107-2114.
21. Drovdlik C.M., Goddard K.A.B., Chak A., et al. Demographic and phenotypic features of 70 families segregating Barrett's esophagus and esophageal adenocarcinoma. J Med Genet 2003, 40:651-656.
22. Sappati Biyyani R.S., Chessler L., McCain E., et al. Familial trends of inheritance in gastro-esophageal reflux disease, Barrett's esophagus and Barrett's adenocarcinoma: 20 families. Dis Esophagus 2007, 20:53-57.
23. Cameron A.J., Lagergren J., Henriksson C., et al. Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology 2002, 122:55-59.
24. Mohammed I., Cherkas L.F., Riley S.A., et al. Genetic influences in gastro-esophageal reflux disease: a twin study. Gut 2003, 52:1085-1089.
25. Zaman M.S., Hur C., Jones M.P., et al. Concordance of reflux among monozygotic and dizygotic twins. Gastroenterology 2001, 120(Suppl 5):A418.
26. Cheung W.Y., Liu G. Genetic variations in esophageal cancer risk and prognosis. Gastroenterol Clin North Am 2009, 38:75-91.
27. Lee C.H., Lee J.M., Wu D.C., et al. Carcinogenetic impact of ADH1B and ALDH2 genes on squamous cell carcinoma risk of the esophagus with regard to the consumption of alcohol, tobacco, and betel quid. Int J Cancer 2008, 122(6):1347-1356.
28. Lewis S.J., Smith G.D. Alcohol, ALDH2, and esophageal cancer: a meta-analysis which illustrates the potentials and limitations of a Mendelian randomization approach. Cancer Epidemiol Biomarkers Prev 2005, 14:1967-1971.
29. Doecke J., Zhao Z.Z., Pandeya N., et al. Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma. Int J Cancer 2008, 123:174-180.
30. Parkin D.M., Bray F.I., Ferlay J., et al. Global cancer statistics: 2002. CA Cancer J Clin 2005, 55:74-108.
31. Cancer facts and figures 2008, 4-17. American Cancer Society, American Cancer Society, Atlanta.
32. Lauren T. The two histologic main types of gastric carcinoma. Acta Pathol Microbiol Scand 1965, 64:34.
33. Munoz N., Correa P., Cuello C., et al. Histologic types of gastric carcinoma in high- and low-risk areas. Int J Cancer 1968, 3:809-818.
34. Nagase H., Ogino K., Yoshida I., et al. Family history-related risk of gastric cancer in Japan: a hospital-based case-control study. Jpn J Cancer Res 1996, 87(10):1025-1028.
35. Palli D., Galli M., Caporaso N.E., et al. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev 1994, 3(1):15-18.
36. Zanghieri G., Di Gregorio C., Sacchetti C., et al. Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. Cancer 1990, 66:2047-2051.
37. Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer. N Engl J Med 2000, 343(2):78-85.
38. Caldas C., Carniero F., Lynch H.T., et al. Familial gastric cancer: overview and guidelines for management. J Med Genet 1999, 36:873-880.
39. Guilford P., Hopkins J., Harraway J., et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998, 392:402-405.
40. Guilford P.J., Hopkins J.B., Grady W.M., et al. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat 1999, 14(3):249-255.
41. Oliveira C., Senz J., Kaurah P., et al. Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet 2009, 18(9):1545-1555.
42. Kaurah P., MacMillan A., Boyd N., et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007, 297(21):2360-2372.
43. Pinheiro H., Bordeira-Carrico R., Seixas S., et al. Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet 2010, 19(5):943-952.
44. Huntsman D.G., Carneiro F., Lewis F.R., et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001, 344(25):1904-1909.
45. Lynch H.T., Grady W., Suriano G., et al. Gastric cancer: new genetic developments. J Surg Oncol 2005, 90(3):114-133.
46. Lynch H.T., Lanspa S.J., Boman B.M., et al. Hereditary nonpolyposis colorectal cancer-Lynch syndromes I and II. Gastroenterol Clin North Am 1988, 17(4):679-712.
47. Lynch H.T., Lynch P.M., Lanspa S.J., et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009, 76(1):1-18.
48. Aarnio M., Salovaara R., Aaltonen L., et al. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer 1997, 74(5):551-555.
49. Vasen H.F., Wijnen J.T., Menko F.H., et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996, 110(4):1020-1027.
50. Bodmer W.F., Bailey C.J., Bodmer J., et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1987, 328:614-616.
51. Groden J., Thliveris A., Samowitz W., et al. Identification and characterization of the familial adenomatous polyposis gene. Cell 1991, 66:589-600.
52. Vogelstein B., Kinzler K.W. The multistep nature of cancer. Trends Genet 1993, 9:138-141.
53. Gallagher M.C., Phillips R.K., Bulow S. Surveillance and management of upper gastrointestinal disease in familial adenomatous polyposis. Fam Cancer 2006, 5:263-273.
54. Offerhaus G.J., Giardiello F.M., Krush A.J., et al. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 1992, 102:1980-1982.
55. Oliveira C., Ferreira P., Nabais S., et al. E-cadherin, CDH1, and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. Eur J Cancer 2004, 40:1897-1903.
56. Peek R.M., Blaser M.J. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002, 2:28-37.
57. Uemura N., Okamoto S., Yamamoto S., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001, 345(11):784-789.
58. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994, 61:1-241.
59. Everhart J.E., Kruszon-Moron D., Perez-Perez G.I., et al. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis 2000, 181:1359-1363.
60. Dunn B.E., Cohen H., Blazer M.J. Helicobacter pylori. Clin Microbiol Rev 1997, 10:720-741.
61. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 1996, 87(6):2095-2147.
62. Basso D., Scrigner M., Toma A., et al. Helicobacter pylori infection enhances mucosal interleukin-1 beta, interleukin-6, and the soluble receptor of interleukin-2. Int J Clin Lab Res 1996, 26:207-210.
63. El Omar E.M., Carrington M., Chow W.H., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000, 404:398-402.
64. Figueiredo C., Machado J.C., Pharoah P., et al. Helicobacter pylori and interleukin-1 genotyping: an opportunity to identify high-risk individuals for gastric adenocarcinoma. J Natl Cancer Inst 2002, 94(22):1680-1687.
65. Li C., Xia H.H., Xie W., et al. Association between interleukin-1 gene populations and Helicobacter pylori infection in gastric carcinogenesis in a Chinese population. J Gastroenterol Hepatol 2007, 22(2):234-239.
66. Taguchi A., Ohmiya N., Shirai K., et al. Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. Cancer Epidemiol Biomarkers Prev 2005, 15:2487-2493.
67. Sharma S.A., Tummuru M.K., Blaser M.J., et al. Activation of IL-8 gene expression by Helicobacter pylori is regulated by transcription factor nuclear factor-B in gastric epithelial cells. J Immunol 1998, 160:2401-2407.
68. Karin M., Cao Y., Greten F.R., et al. NF-kB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2:301-310.
69. Sasaki N., Morisaki T., Hashizume K., et al. Nuclear factor-kB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 2001, 7:4136-4142.
70. Lee W.P., Tai D.I., Lan K.H., et al. The -251T allele of the interleukin-8 promoter is associated with increased risk of gastric carcinoma featuring diffuse-type histopathology in Chinese population. Clin Cancer Res 2005, 11(18):6431-6441.
71. Gianfagna F., De Feo E., Van Duijn C.M., et al. A systematic review of meta-analyses on gene polymorphisms and gastric cancer risk. Curr Genomics 2008, 9:361-374.
72. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer statistics, 2001. CA Cancer J Clin 2001, 51(1):15-36.
73. Klein A.P., Hruban R.H., Brune K.A., et al. Familial pancreatic cancer. Cancer J 2001, 7(4):266-273.
74. Brand R.E., Lynch H.T. Hereditary pancreatic adenocarcinoma. A clinical perspective. Med Clin North Am 2000, 84(3):665-675.
75. Lynch H.T., Brand R.E., Deters C.A., et al. Hereditary pancreatic cancer. Pancreatology 2001, 1(5):466-471.
76. Bishop D.T. BRCA1 and BRCA2 and breast cancer incidence: a review. Ann Oncol 1999, 10(Suppl 6):113-119.
77. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999, 91(15):1310-1316.
78. Murphy K.M., Brune K.A., Griffin C., et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002, 62(13):3789-3793.
79. Lynch H.T., Detres C.A., Snyder C.L., et al. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet 2005, 158(2):119-125.
80. Thompson D., Easton D.F. Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002, 94(18):1358-1365.
81. Lynch H.T., Voorhees G.J., Lanspa S.J., et al. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer 1985, 52(2):271-273.
82. Umar A., Boland C.R., Terdiman J.P., et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96(4):261-268.
83. Geary J., Sasieni P., Houlston R., et al. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer 2008, 7(2):163-172.
84. Wilentz R.E., Goggins M., Redston M., et al. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: a newly described and characterized entity. Am J Pathol 2000, 156(5):1641-1651.
85. Banville N., Geraghty R., Fox E., et al. Medullary carcinoma of the pancreas in a man with hereditary nonpolyposis colorectal cancer due to a mutation of the MSH2 mismatch repair gene. Hum Pathol 2006, 37(11):1498-1502.
86. Gargiulo S., Torrini M., Ollila S., et al. Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome. Fam Cancer 2009, 8(4):547-553.
87. Kastrinos F., Mukherjee B., Tayob N., et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009, 302(16):1790-1795.
88. Yamamoto H., Itoh F., Nakamura H., et al. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res 2001, 61(7):3139-3144.
89. Goldstein A.M. Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat 2004, 23(6):630.
90. Bergman W., Gruis N. Familial melanoma and pancreatic cancer. N Engl J Med 1996, 334(7):471-472.
91. Bergman W., Watson P., de Jong J., et al. Systemic cancer and the FAMMM syndrome. Br J Cancer 1990, 61(6):932-936.
92. Borg A., Sandberg T., Nilsson K., et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000, 92(15):1260-1266.
93. Vasen H.F., Gruis N.A., Frants R.R., et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000, 87(6):809-811.
94. Lynch H.T., Brand R.E., Hogg D., et al. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 2002, 94(1):84-96.
95. Giardiello F.M., Trimbath J.D. Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 2006, 4(4):408-415.
96. Giardiello F.M., Welsh S.B., Hamilton S.R., et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 1987, 316(24):1511-1514.
97. Hearle N., Schumacher V., Menko F.H., et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006, 12(10):3209-3215.
98. Giardiello F.M., Brensinger J.D., Tersmette A.C., et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000, 119(6):1447-1453.
99. Lim W., Olschwang S., Keller J.J., et al. Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology 2004, 126(7):1788-1794.
100. Giardiello F.M., Offerhaus G.J., Lee D.H., et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993, 34(10):1394-1396.
101. Groen E.J., Roos A., Muntinghe F.L., et al. Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol 2008, 15(9):2439-2450.
102. Horii A., Nakatsuru S., Miyoshi Y., et al. Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res 1992, 52(23):6696-6698.
103. Gupta C., Mazzara P.F. High-grade pancreatic intraepithelial neoplasia in a patient with familial adenomatous polyposis. Arch Pathol Lab Med 2005, 129(11):1398-1400.
104. Lowenfels A.B., Maisonneuve P., DiMagno E.P., et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997, 89(6):442-446.
105. Whitcomb D.C., Gorry M.C., Preston R.A., et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996, 14(2):141-145.
106. Reimer R.R., Fraumeni J.F., Ozols R.F., et al. Pancreatic cancer in father and son. Lancet 1977, 1(8017):911.
107. Ehrenthal D., Haeger L., Griffin T., et al. Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. Cancer 1987, 59(9):1661-1664.
108. Ghadirian P., Boyle P., Simard A., et al. Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int J Pancreatol 1991, 10(3-4):183-196.
109. Lynch H.T., Fitzsimmons M.L., Smyrk T.C., et al. Familial pancreatic cancer: clinicopathologic study of 18 nuclear families. Am J Gastroenterol 1990, 85(1):54-60.
110. Hruban R.H., Petersen G.M., Goggins M., et al. Familial pancreatic cancer. Ann Oncol 1999, 10(Suppl 4):69-73.
111. Lal G., Liu G., Schmocker B., et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 2000, 60(2):409-416.
112. Klein A.P., Beaty T.H., Bailey-Wilson J.E., et al. Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol 2002, 23(2):133-149.
113. Tersmette A.C., Petersen G.M., Offerhaus G.J., et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001, 7(3):738-744.
114. Klein A.P., Brune K.A., Petersen G.M., et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004, 64(7):2634-2638.
115. Pogue-Geile K.L., Chen R., Bonner M.P., et al. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med 2006, 3(12):e516.
116. Klein A.P., de Andrade M., Hruban R.H., et al. Linkage analysis of chromosome 4 in families with familial pancreatic cancer. Cancer Biol Ther 2007, 6(3):320-323.
117. Slater E., Amrillaeva V., Fendrich V., et al. Palladin mutation causes familial pancreatic cancer: absence in European families. PLoS Med 2007, 4(4):e164.
118. Zogopoulos G., Rothenmund H., Eppel A., et al. The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. Hum Genet 2007, 121(5):635-637.
119. Klein A.P., Borges M., Griffith M., et al. Absence of deleterious palladin mutations in patients with familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2009, 18(4):1328-1330.
120. Greenhalf W., Malats N., Nilsson M., et al. International registries of families at high risk of pancreatic cancer. Pancreatology 2008, 8(6):558-565.
121. Singh M., Maitra A. Precursor lesions of pancreatic cancer: molecular pathology and clinical implications. Pancreatology 2007, 7(1):9-19.
122. Brentnall T.A., Bronner M.P., Byrd D.R., et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999, 131(4):247-255.
123. Canto M.I., Goggins M., Yeo C.J., et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004, 2(7):606-621.
124. Canto M.I., Goggins M., Hruban R.H., et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006, 4(6):766-781. [quiz 665].
125. Langer P., Kann P.H., Fendrich V., et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009, 58(10):1410-1418.
126. Brand R.E., Lerch M.M., Rubinstein W.S., et al. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007, 56(10):1460-1469.
127. Kindblom L.G., Remotti H.E., Aldenborg F., et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998, 152(5):1259-1269.
128. Mazur M.T., Clark H.B. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983, 7(6):507-519.
129. Miettinen M., Majidi M., Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002, 38(Suppl 5):S39-S51.
130. Reichardt P., Hogendoorn P.C., Tamborini E., et al. Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. Semin Oncol 2009, 36(4):290-301.
131. Stamatakos M., Douzinas E., Stefanaki C., et al. Gastrointestinal stromal tumor. World J Surg Oncol 2009, 7:61.
132. Hirota S., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279(5350):577-580.
133. Kingham T.P., DeMatteo R.P. Multidisciplinary treatment of gastrointestinal stromal tumors. Surg Clin North Am 2009, 89(1):217-233. x.
134. DeMatteo R.P. Nanoneoadjuvant therapy of gastrointestinal stromal tumor (GIST). Ann Surg Oncol 2009, 16(4):799-800.
135. Nishida T., Hirota S., Taniguchi M., et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998, 19(4):323-324.
136. Agarwal R., Robson M. Inherited predisposition to gastrointestinal stromal tumor. Hematol Oncol Clin North Am 2009, 23(1):1-13. vii.
137. Robson M.E., Glogowski E., Sommer G., et al. Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clin Cancer Res 2004, 10(4):1250-1254.
138. Kleinbaum E.P., Lazar A.J., Tamborini E., et al. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor. Int J Cancer 2008, 122(3):711-718.
139. Marshall J.B., Diaz-Arias A.A., Bochna G.S., et al. Achalasia due to diffuse esophageal eiomyomatosis and inherited as an autosomal dominant disorder. Report of a family study. Gastroenterology 1990, 98(5 pt 1):1358-1365.
140. Agaimy A., Pelz A.F., Corless C.L., et al. Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridization. Oncol Rep 2007, 18(1):9-15.
141. Knop S., Schupp M., Warderlmann E., et al. A new case of Carney triad: gastrointestinal tumours and leiomyoma of the oesophagus do not show activating mutations of KIT and platelet-derived growth factor receptor alpha. J Clin Pathol 2006, 59(10):1097-1099.
142. Fuller C.E., Williams G.T. Gastrointestinal manifestations of type 1 neurofibromatosis (von Recklinghausen's disease). Histopathology 1991, 19(1):1-11.